COST UTILITY ANALYSIS OF THE PROFILAXIS VERSUS ON-DEMAND TREATMENT WITH RECOMBINANT FACTOR IX FOR THE TREATMENT OF HEMOPHILIA B IN MEXICO

被引：1
|
作者：
Mucino-Ortega, E. [1 ]
Leyva-Bravo, V [2 ]
Gutierrez, C. [1 ]
Galindo-Suarez, R. M. [1 ]
机构：
[1] Pfizer SA CV, Mexico City, DF, Mexico
[2] IMS Hlth Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.564
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A103 / A104
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
    Pochopien, Michal
    Tytula, Anna
    Toumi, Mondher
    Falk, Aletta
    Martone, Nicoletta
    Hakimi, Zalmai
    Eriksson, Daniel
    [J]. ADVANCES IN THERAPY, 2024, 41 (06) : 2307 - 2323
  • [2] Cost-utility study of recombinant factor VIII in the treatment of hemophilia a in Mexico
    Soria-Cedillo, I. F.
    De la Mora-Chavez, T.
    Del Campo-Perez, M.
    Brugada-Cruces, C.
    Garcia-Contreras, F.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A162 - A162
  • [3] Cost-utility study of recombinant factor VIII in the treatment of hemophilia A in Mexico
    Garcia-Contreras, F.
    De La Mora-Chavez, T.
    Del Campo-Perez, M.
    Brugada-Cruces, C.
    Soria-Cedillo, I.
    [J]. HAEMOPHILIA, 2008, 14 : 134 - 134
  • [4] Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
    Rasekh, Hamid Reza
    Imani, Ali
    Karimi, Mehran
    Golestani, Mina
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 207 - 212
  • [5] Treatment of hemophilia B: focus on recombinant factor IX
    Franchini, Massimo
    Frattini, Francesco
    Crestani, Silvia
    Sissa, Cinzia
    Bonfanti, Carlo
    [J]. BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 33 - 38
  • [6] Recombinant factor IX Fc for the treatment of hemophilia B
    Ljung, Rolf
    Matino, Davide
    Shapiro, Amy D.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (05) : 678 - 691
  • [7] Recombinant factor IX for the treatment of hemophilia B - Introduction
    Thompson, A
    [J]. SEMINARS IN HEMATOLOGY, 1998, 35 (02) : 1 - 3
  • [8] Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Mancuso, Maria Elisa
    Santagostino, Elena
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 55 - 61
  • [9] COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS VERSUS ON-DEMAND SUPPLY OF FACTOR IX IN PATIENTS DIAGNOSED WITH SEVERE HEMOPHILIA B IN COLOMBIA
    Ordonez Molina, J. E.
    Orozco Giraldo, J. J.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A104 - A105
  • [10] Prophylactic versus On-Demand Treatment with rFVIIa in Hemophilia Patients with Inhibitors: An Incremental Cost Analysis
    Doti, C.
    [J]. HAEMOPHILIA, 2012, 18 : 68 - 68
12345